Michael Keng
- Hematology top 10%
- Acute Myeloid Leukemia Research 13
- Chronic Myeloid Leukemia Treatments 6
- Clinical Biochemistry top 10%
-
- Neutropenia and Cancer Infections 14
- CAR-T cell therapy research 5
-
- Acute Lymphoblastic Leukemia research 16
-
- Chronic Lymphocytic Leukemia Research 5
-
- Childhood Cancer Survivors' Quality of Life 5
-
- Mycobacterium research and diagnosis 4
Michael Keng
46 papers receiving 441 citations
Peers
Comparison fields: 5 of 76
- Hematology 148
- Clinical Biochemistry 57
- Oncology 182
- Public Health, Environmental and Occupational Health 106
- Emergency Medicine 35
Countries citing papers authored by Michael Keng
This map shows the geographic impact of Michael Keng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Keng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Keng more than expected).
Fields of papers citing papers by Michael Keng
This network shows the impact of papers produced by Michael Keng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Keng. The network helps show where Michael Keng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Keng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 7 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 4 | |
| 8 | 2022 | 12 | |
| 9 | 2022 | 8 | |
| 10 | 2021 | 3 | |
| 11 | 2020 | 48 | |
| 12 | 2019 | 16 | |
| 13 | 2018 | 1 | |
| 14 | 2018 | 14 | |
| 15 | 2018 | 3 | |
| 16 | 2017 | 31 | |
| 17 | 2015 | 13 | |
| 18 | 2014 | 1 | |
| 19 | 2013 | 45 | |
| 20 | 2003 | 79 |
About Michael Keng
Michael Keng is a scholar working on Hematology, Oncology and Geriatrics and Gerontology, having authored 52 papers that have together received 453 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (16 papers), Neutropenia and Cancer Infections (14 papers), Acute Myeloid Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Childhood Cancer Survivors' Quality of Life (5 papers), CAR-T cell therapy research (5 papers) and Mycobacterium research and diagnosis (4 papers). The work is most often cited by research in Hematology (148 citations), Clinical Biochemistry (57 citations) and Oncology (182 citations). Michael Keng has collaborated with scholars based in United States, Australia and Poland. Frequent co-authors include Mikkael A. Sekeres, Firas El Chaer, Amy Morris, Karen K. Ballen, Daniel Reed, Rainer Storb, David G. Maloney, Michael Boeckh, Brenda M. Sandmaier and Michael B. Maris. Their work appears in journals such as Blood, Journal of Clinical Oncology, Current Hematologic Malignancy Reports, Journal of Oncology Practice and Open Forum Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.